Ablexis Announces Licensing Agreement with Corvidia Therapeutics
SAN DIEGO--(BUSINESS WIRE)--Jan 3, 2019--Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Corvidia Therapeutics Inc. The non-exclusive license grants Corvidia rights to use the AlivaMab Mouse for antibody drug discovery and development. Financial terms of the license include an upfront payment, development milestones and a royalty on product sales.
About Ablexis, LLC Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has non-exclusively licensed the AlivaMab Mouse technology to multiple companies, including global pharmaceutical companies, public and private biotechnology companies and other entities. Ablexis continues making the AlivaMab Mouse available via non-exclusive licenses. For more information, visit www.ablexis.com. For inquiries about licensing AlivaMab Mouse, contact us at firstname.lastname@example.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005037/en/
CONTACT: Christine Quern
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL
SOURCE: Ablexis, LLC
Copyright Business Wire 2019.
PUB: 01/03/2019 07:00 AM/DISC: 01/03/2019 07:01 AM